FDA approves Sorin's updated CRT-D
The FDA has approved Sorin Group’s next-generation cardiac resynchronization therapy defibrillator (CRT-D), the Paradym CRT Model 8750.
Featuring a new battery technology, Paradym CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently. Also, Paradym offers charge times throughout the life of the device (10s at Beginning Of Life, 13s at Elective Replacement Indicator, or ERI) and a six-month ERI to End of Service period, twice as long as any other ICD, the Milan-based company said.
Paradym CRT is designed for the management of cardiac resynchronization and anti-tachyarrhythmia therapy in heart failure patients. Sorin said that Brady-Tachy Overlap is designed to unlock pacing and detection to ensure delivery of resynchronization therapy at high pacing rates during exercise while managing slow ventricular tachycardias.
Featuring a new battery technology, Paradym CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently. Also, Paradym offers charge times throughout the life of the device (10s at Beginning Of Life, 13s at Elective Replacement Indicator, or ERI) and a six-month ERI to End of Service period, twice as long as any other ICD, the Milan-based company said.
Paradym CRT is designed for the management of cardiac resynchronization and anti-tachyarrhythmia therapy in heart failure patients. Sorin said that Brady-Tachy Overlap is designed to unlock pacing and detection to ensure delivery of resynchronization therapy at high pacing rates during exercise while managing slow ventricular tachycardias.